Citations

Clear

1575 citation(s) found for "Im, Gene".

Bacterial gene control by DNA looping using engineered dimeric transcription activator like effector (TALE) proteins
Becker, Nicole A. , Schwab, Tanya L., Clark, Karl J. , Maher, L. James, Clark, Karl J

Mayo Clinic

Nucleic Acids Research | January 18, 2018 | Volume: 46 | Issue: 5 | Pages: 2690-2696

10.1093/nar/gky047 | PMID 29390154 Get It

Assessing the underlying pattern of human germline mutations: lessons from the factor IX gene
Sommer, Steve S.

Mayo Clinic

The FASEB Journal | January 18, 2018 | Volume: 6 | Issue: 10 | Pages: 2767-2774

10.1096/fasebj.6.10.1634040 | PMID 1634040 Get It

Germline mutations cause or predispose to most diseases. Hemophilia B is a useful model for studying the underlying pattern of recent germline mutations in humans because the observed pattern of mutation in factor IX more closely reflects the underlying pattern of mutation than the observed pattern for many other genes. In addition, it is possible to identify and correct for biases inherent in ascertaining only those mutations that cause hemophilia. Aspects of the pattern of germline mutation in the factor IX gene are becoming clear: 1 ) in the United States, two‐thirds of mutations causing mild disease arose from three founders whereas almost all the mutations resulting in either moderate or severe disease arose independently, generally within the past 150 years; 2 ) direct estimates of the rates of mutation in humans indicate that transitions are more frequent than transversions, which in turn are more frequent than deletions and insertions; 3 ) transitions at CpG are elevated approximately 24‐fold relative to transitions at non‐CpG dinucleotides; 4 ) transversions at CpG are elevated approximately eightfold relative to transversions at non‐CpG dinucleotides; 5 ) the sum total of the dinucleotide mutation rates produces a bias against G and C bases that would be sufficient to maintain the G+C content of the factor IX gene at its evolutionarily conserved level of 40%; and 6 ) the pattern of mutation is similar for Caucasians residing in the United States and for Asians residing in Asia. Two ideas emerge from this and from an analysis of the pattern of recent deleterious mutations compared with ancient neutral mutations that have been fixed during evolution into the factor IX gene. First, the bulk of germline mutations are likely to arise from endogenous processes rather than environmental mutagens. Second, the factor IX protein is composed mostly of two classes of amino acids: critical residues in which all single‐base missense changes will disrupt protein function, and “spacer” residues in which the precise nature of the residue is unimportant but the peptide bond is necessary to keep the critical residues in register. More work is necessary to assess the veracity and generality of these ideas.— Sommer, S. S. Assessing the underlying pattern of human germline mutations: lessons from the factor IX gene. FASEB J. 6: 2767‐2774; 1992.
Cloning of the murine eosinophil peroxidase gene (mEPO): characterization of a conserved subgroup of mammalian hematopoietic peroxidases
Horton, Margaret A., Larson, Kirsten A., Lee, Nancy A., Lee, James J.

Mayo Clinic

Journal of Leukocyte Biology | January 12, 2018 | Volume: 60 | Issue: 2 | Pages: 285-294

10.1002/jlb.60.2.285 | PMID 8773591 Get It

Abstract The mouse eosinophil peroxidase (mEPO) gene was cloned by screening a random-primed bone marrow cDNA library at reduced criteria using a hEPO cDNA. An mEPO cDNA was subsequently used to isolate the mEPO gene from a λ-genomic library. The mEPO gene displays a high degree of conservation with its human homologue: the transcription units are approximately the same size, conserve the relative size and position of the 12 exons associated with each gene, and at a nucleotide level the mouse and human EPO genes are 86% identical in the protein coding regions and 66% identical in the 3'-untranslated trailer regions. This strong conservation extends to the encoded proteins which show ~90% amino acid identity. Expression of the mEPO gene is restricted to tissues containing eosinophil progenitor cells (e.g., bone marrow and spleen), a pattern similar to the expression of another murine eosinophil granule protein, major basic protein.
Identification of a new murine eosinophil major basic protein (mMBP) gene: cloning and characterization of mMBP-2
Macias, MiMi P. , Denzler, Karen L., Larson, Kirsten A., Lee, Nancy A., Welch, Kenneth C. , Lee, James J.

Mayo Clinic

Journal of Leukocyte Biology | January 12, 2018 | Volume: 67 | Issue: 4 | Pages: 567-576

10.1002/jlb.67.4.567 | PMID 10770291 Get It

Abstract We have identified a new eosinophil major basic protein gene family member in the mouse and have given it the designation murine major basic protein-2 (mMBP-2). The gene was initially characterized as a unique expressed sequence tag (EST) clone having significant identity to the previously recognized member of this gene family, mMBP-1. The EST was used to screen and isolate mMBP-2 from a bone marrow cDNA library. In addition, a genomic clone of mMBP-2 was isolated and this gene was shown to be physically linked to within 100 kb of mMBP-1 on the central region of mouse chromosome 2. Progressive similarity alignment of the deduced mMBP-2 open reading frame demonstrates the apparent conservation of the “pre-pro-mature” protein structure found in the other known mammalian MBPs. Mature mMBP-2 maintains the cationic nature associated with these proteins with a predicted pI of 9.95. However, unlike the human MBPs, which display a three orders of magnitude charge difference [hMBP-1 (pI11.4) vs. hMBP-2 (pI8.7)], mMBP-2 is only slightly less cationic than mMBP-1 (pI 10.5). Expression studies demonstrate that transcription of the mMBP-2 gene parallels mMBP-1 and is confined to hematopoietic compartments engaged in eosinophilopoiesis. Moreover, using mMBP-1 knockout mice and immunohistochemistry with an antisera that recognizes both mMBP-1 and -2, we demonstrate that mMBP-2 protein expression is restricted to eosinophil lineage-committed cells. J. Leukoc. Biol. 67: 567–576; 2000.
PANDA: pathway and annotation explorer for visualizing and interpreting gene-centric data
Moore, Raymond M. , Egan, Jan B. , Kocher, Jean-Pierre A., Hart, Steven N. , Zimmermann, Michael T. , Oliver, Gavin R. , Bryce, Alan H.

Mayo Clinic

No container title available | January 12, 2018 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7287/peerj.preprints.1021v1 Get It

Objective: Bringing together genomics, transcriptomics, proteomics, and other –omics technologies is an important step towards developing highly personalized medicine. However, instrumentation has advances far beyond expectations and now we are able to generate data faster than it can be interpreted. Materials and Methods: We have developed PANDA ( P athway AND A nnotation) Explorer, a visualization tool that integrates gene-level annotation in the context of biological pathways to help interpret complex data from disparate sources. PANDA is a web-based application that displays data in the context of well-studied pathways like KEGG, BioCarta, and PharmGKB. PANDA represents data/annotations as icons in the graph while maintaining the other data elements (i.e. other columns for the table of annotations). Custom pathways from underrepresented diseases can be imported when existing data sources are inadequate. PANDA also allows sharing annotations among collaborators. Results : In our first use case, we show how easy it is to view supplemental data from a manuscript in the context of a user’s own data. Another use-case is provided describing how PANDA was leveraged to design a treatment strategy from the somatic variants found in the tumor of a patient with metastatic sarcomatoid renal cell carcinoma. Conclusion : PANDA facilitates the interpretation of gene-centric annotations by visually integrating this information with context of biological pathways. The application can be downloaded or used directly from our website http://bioinformaticstools.mayo.edu/research/panda-viewer/.
Gene‐Specific Variant Classifier (DPYD‐Varifier) to Identify Deleterious Alleles of Dihydropyrimidine Dehydrogenase
Zhang, Cheng , Jerde, Calvin R. , Nie, Qian , Offer, Steven M. , Diasio, Robert B. , Shrestha, Shikshya , Zhang, Cheng , Li, Hu , Offer, Steven M

Mayo Clinic

Clinical Pharmacology & Therapeutics | January 12, 2018 | Volume: 104 | Issue: 4 | Pages: 709-718

10.1002/cpt.1020 | PMID 29327356 Get It

Deleterious variants in dihydropyrimidine dehydrogenase (DPD, DPYD gene) can be highly predictive of clinical toxicity to the widely prescribed chemotherapeutic 5‐fluorouracil (5‐FU). However, there are very limited data pertaining to the functional consequences of the >450 reported no‐synonymous DPYD variants. We developed a DPYD‐specific variant classifier (DPYD‐Varifier) using machine learning and in vitro functional data for 156 missense DPYD variants. The developed model showed 85% accuracy and outperformed other in silico prediction tools. An examination of feature importance within the model provided additional insight into functional aspects of the DPD protein relevant to 5‐FU toxicity. In the absence of clinical data for unstudied variants, prediction tools like DPYD‐Varifier have great potential to individualize medicine and improve the clinical decision‐making process.
Mutational Alterations of the p16CDKN2A Tumor Suppressor Gene Have Low Incidence in Mesenchymal Chondrosarcoma
Bae, Dae Kyung , Yk, Park, Chi, S.-G., Unni, K. Krishnan, Lee, C.W.

Mayo Clinic

Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics | January 5, 2018 | Volume: 12 | Issue: 1 | Pages: 5-10

10.3727/000000001108747381 | PMID 11061340 Get It

Gene Expression Profiling and Assessment of Vitamin D and Serotonin Pathway Variations in Patients With Irritable Bowel Syndrome
Dussik, Christopher M. , Hockley, Maryam, Grozić, Aleksandra, Kaneko, Ichiro , Zhang, Lin , Sabir, Marya S. , Nickerson, Cheryl A. , Yale, Steven H. , Rall, Christopher, Foxx–Orenstein, Amy E., Borror, Connie M., Sandrin, Todd R. , Foxx-Orenstein, Amy E, Park, Jin Kee , Wang, Jie , Jurutka, Peter W.

Mayo Clinic

Journal of Neurogastroenterology and Motility | January 2, 2018 | Volume: 24 | Issue: 1 | Pages: 96-106

10.5056/jnm17021 | PMID 29291611 Get It

Disuse osteopenia is accompanied by downregulation of gene expression for bone proteins in growing rats
Wakley, Glenn K., Portwood, J. S., Turner, Russell T.

Mayo Clinic

American Journal of Physiology-Endocrinology and Metabolism | December 25, 2017 | Volume: 263 | Issue: 6 | Pages: E1029-E1034

10.1152/ajpendo.1992.263.6.e1029 Get It

Unilateral sciatic neurectomy (USN) resulted in cortical osteopenia in tibiae from the sciatic nerve-sectioned limb of growing rats. The bone deficit resulted from decreased periosteal addition; there were no changes in the indexes of bone resorption. The periosteal bone formation rate was reduced in the nerve-sectioned limb within 7 days of sciatic neurectomy, and this decrease persisted for at least 56 days. Steady-state mRNA levels for bone proteins were determined in periosteum isolated from tibiae and femurs 7 and 14 days after sciatic nerve section. Nerve section resulted in decreased levels of mRNA for osteocalcin, alkaline phosphatase, and possibly the prepro-alpha (I)-subunit of type I collagen (collagen). The effects were more pronounced in tibiae than femurs, corresponding to the greater degree of immobility induced by USN in the former bone. The results demonstrate that decreased bone formation precedes establishment of disuse cortical osteopenia in growing rats with no evidence for a change in bone resorption. Furthermore, the decreased bone formation is associated with, and may be due to, reduced mRNA levels for matrix proteins and other important bone proteins.
Gene transfer of recombinant endothelial nitric oxide synthase to liver in vivo and in vitro
Shah, Vijay H. , Chen, Alex F. , Cao, Sheng , Hendrickson, Helen, Weiler, Deb, Yao, Janet , Katušić, Zvonimir S. , Smith, Leslie

Mayo Clinic

American Journal of Physiology-Gastrointestinal and Liver Physiology | December 24, 2017 | Volume: 279 | Issue: 5 | Pages: G1023-G1030

10.1152/ajpgi.2000.279.5.g1023 | PMID 11053000 Get It

Endothelial nitric oxide synthase (eNOS)-derived nitric oxide (NO) contributes to hepatic vascular homeostasis. The aim of this study was to examine whether delivery of an adenoviral vector encoding eNOS gene to liver affects vasomotor function in vivo and the mechanism of NO production in vitro. Rats were administered adenoviruses encoding β-galactosidase (AdCMVLacZ) or eNOS (AdCMVeNOS) via tail vein injection and studied 1 wk later. In animals transduced with AdCMVLacZ, β-galactosidase activity was increased in the liver, most prominently in hepatocytes. In AdCMVeNOS-transduced animals, eNOS protein levels and catalytic activity were significantly increased. Overexpression of eNOS diminished baseline perfusion pressure and constriction in response to the α1-agonist methoxamine in the perfused liver. Transduction of cultured hepatocytes with AdCMVeNOS resulted in the targeting of recombinant eNOS to a perinuclear distribution and binding with the NOS-activating protein heat shock protein 90. These events were associated with increased ionomycin-stimulated NO release. In summary, this is the first study to demonstrate successful delivery of the recombinant eNOS gene to liver in vivo and in vitro with ensuing NO production.